Back to Oncology
Oncologyv2011Evidence-Based

Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score

Predicts small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset. The score helps identify high-risk patients requiring intensive cancer screening.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
delta p score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

DELTA-P Score = Sum of points for: Age ≥50 years (1 point) + Current smoking (1 point) + Weight loss >5% (1 point) + Bulbar involvement (1 point) + Erectile dysfunction in males (1 point) + Karnofsky performance status <70 (1 point). Score ranges from 0-6 points with higher scores indicating increased SCLC risk.

Clinical Pearls & Practice Notes

  • Developed using Dutch (n=107) and British (n=112) cohorts of LEMS patients.
  • Validated prospectively with area under ROC curve of 82.5% (95% CI 73.9-91%).
  • Each parameter must be assessed at or within 3 months of LEMS symptom onset.
  • Lambert-Eaton myasthenic syndrome affects approximately 1 in 100,000 individuals.
  • About 50-60% of LEMS patients have underlying small-cell lung cancer (SCLC-LEMS).
  • The remaining 40-50% have non-tumor LEMS (NT-LEMS) with different prognosis.
  • SCLC-LEMS patients typically have more severe symptoms and poorer functional status.
  • Early cancer detection is crucial as SCLC has poor prognosis with median survival <2 years.
  • Treatment of underlying SCLC can improve LEMS symptoms in some patients.
  • Score should be used in conjunction with clinical judgment and other diagnostic markers.
  • SOX antibodies are also associated with SCLC-LEMS and can complement this scoring system.
  • High-risk patients (score ≥3) should undergo screening every 3 months per guidelines.
  • Karnofsky Performance Status: 100=normal, 90=minor symptoms, 80=normal activity with effort, 70=unable to carry on normal activity but self-care, 60=requires occasional assistance, 50=requires considerable assistance, 40=disabled/requires special care, 30=severely disabled, 20=very sick, 10=moribund.
  • Bulbar symptoms include dysphagia (difficulty swallowing), dysarthria (difficulty speaking), ptosis (drooping eyelids), and diplopia (double vision).
  • LEMS typically presents with proximal muscle weakness, autonomic dysfunction, and reduced deep tendon reflexes.

Evidence & Literature Citations

  1. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-81. doi: 10.1200/JCO.2008.17.1302.
  2. Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27(26):4260-7. doi: 10.1200/JCO.2008.20.6169.
  3. Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-8. doi: 10.1200/JCO.2010.32.0440.
  4. van Sonderen A, Wirtz PW, Verschuuren JJ, Titulaer MJ. Paraneoplastic syndromes of the neuromuscular junction: therapeutic implications. Brain. 2016;139(Pt 10):2759-71. doi: 10.1093/brain/aww199.

Score Interpretation Ranges

Very Low Risk0 – 1 pts

SCLC virtually excluded

Low-Moderate Risk2 – 2 pts

Low to moderate SCLC risk

High Risk3 – 6 pts

High SCLC risk - intensive screening required

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.